Drugs / Peptide vaccine
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT00874861 | Apr 2009 → May 2012 | astrocytoma (excluding glioblastoma), oligoastrocytoma, oligodendroglioma | Ian F. Pollack, M.D. | Completed | No outcome recorded |
| Phase 11 trial | ||||||
| Phase 1 | NCT00471471 | Oct 2008 → Dec 2011 | conjunctival cancer, cutaneous melanoma, ocular melanoma | Ahmad Tarhini | Completed | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT02429440 | May 2005 → Oct 2017 | renal cell carcinoma | University Hospital Tuebingen | Unknown | No outcome recorded |
| Phase 1/2 | NCT02452307 | Apr 2004 → Oct 2017 | prostate carcinoma | University Hospital Tuebingen | Unknown | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT02802943 | Oct 2016 → Sep 2022 | chronic lymphocytic leukemia/small lymphocytic lymphoma | University Hospital Tuebingen | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT00694551 | Dec 2008 → Feb 2013 | prostate cancer | H. Lee Moffitt Cancer Center and Research Institute | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Peptide Vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02802943 ↗ |
| Modality | Vaccine | “Patients receive peptide vaccine comprising MART-1:27-35 peptide, gp100:209-217 (210M) peptide, and tyrosinase peptide” NCT00471471 ↗ |
| Route | Subcutaneous | “Vaccination will be given subcutaneously rotating truncal sites” NCT00471471 ↗ |